← boardnext 2030-01
PRME
Prime Medicine, Inc.distress 7/10 · high distress / dilution risk$3.00-3%today-55% from 52w high
Lead: Wilson Disease
Revenue
pre-revenue
Liquidity
$64M
Runway
0.4 yrs
Shares 1y
+34%
Price & events
-35.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.1%
1D
-7.0%
1W
-7.6%
1M
-22.0%
3M
-32.4%
6M
-35.5%
1Y
-48.3%
2Y
—
5Y
-80.5%
All
Overview
- Market Cap
- $540.95M
- Volume
- 304.47K
- 52 Week Range
- $2.70 – $6.67
- Total Shares
- 180.62M
- Float Shares
- 114.96M
- Short %
- 24.61%
- % Held by Insiders
- 23.76%
- % Held by Institutions
- 66.60%
- RVOL
- 0.08x
- Beta
- 2.27
Pipeline stages · 1 programs
PM359
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2030-01 Estimated 50% readout ~2030-02-15 | Phase 1/2 | PM359 | Chronic Granulomatous Disease, Granulomatous Disease, Chronic | — | enrolling by invitation |
Catalyst news & presentations · 4
- 2027Guided 40%readoutPrime Editing for Wilson Disease · Initial clinical data expected.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026regulatory submissionFiled (NDA/BLA)AATD program (Prime Editor) · Expects to file IND and/or CTA for AATD program.SEC 8-K
- 2024-09-28partnershipPrime Editing technology · Exclusive worldwide license to develop and commercialize ex vivo T-cell products for select targetsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $7 (+138% upside) · 10 analysts
- 2026-06-29HC Wainwright & Co.Neutral → Buy
- 2026-03-12OppenheimerOutperform
- 2025-12-23LifeSci CapitalOutperform
- 2025-11-11CitigroupNeutral
- 2025-11-10Chardan CapitalBuy
- 2025-08-12CitigroupNeutral
Competitors — Wilson Disease
Recent news
- 2026-07-18Prime Medicine secures favorable arbitration ruling in Beam Therapeutics case - MSN
- 2026-07-17Prime Medicine secures favorable arbitration ruling in Beam Therapeutics case - MSN
- 2026-07-17PRME Q1 2026 Earnings: EPS Misses Estimates, No Revenue Reported as Stock Declines - Revenue Estimate Trend - dars.gov.et
- 2026-07-15Prime Medicine: A Deep Dive (NASDAQ:PRME) - Seeking Alpha
- 2026-07-15Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME - MarketBeat
- 2026-07-14Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-13Price to earnings forward of Prime Drink Group Corp – NEO:PRME - TradingView
- 2026-07-13Prime Medicine (NASDAQ:PRME) Shares Down 6.5% - Should You Sell? - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.